Antiretroviral drug resistance in human immunodeficiency virus-infected source patients for occupational exposures to healthcare workers

Infection Control and Hospital Epidemiology

Volumn 24, Issue 10, 2003, Pages 724-730

  Beltrami, Elise M ^a   Cheingsong, Rachanee ^b   Heneine, Walid M ^b   Respess, Richard A ^b   Orelien, Jean G ^c   Mendelson, Meryl H ^d   Stewart, Mari A ^e   Koll, Brian S ^f   Sulis, Carol A ^g   Cardo, Denise M ^a   Chen, Bao Ying Lin ^d   Nicholas, Peter ^d   Jones, Sian ^d   Mullen, Michael P ^d   Gordon, Marcia T ^d   Dowdy, Lorraine ^h   Caldwell, Joan ^h   Otten, Joan ^h   Hughson, William ^e   Rymer, Thérèse E ^e   Knowlton, Kim ^f   Derridinger, Olivia ^g   Fazal, Barkat ⁱ   Ogard, Norris ⁱ   Venezia, Richard ^j   Veeder, Abigail ^j   more..

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c Research Triangle Institute   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

^g BOSTON MEDICAL CENTER   (United States)

^h JACKSON MEMORIAL HOSPITAL   (United States)

ⁱ BRONX LEBANON HOSPITAL CENTER   (United States)

^j ALBANY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ENZYME IMMUNOASSAY; GENOTYPE; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; OCCUPATIONAL EXPOSURE; PHENOTYPE; PREVALENCE; VIRUS INFECTION; VIRUS MUTANT; VIRUS RESISTANCE; VIRUS TRANSMISSION; WESTERN BLOTTING;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEALTH PERSONNEL; HIV INFECTIONS; HIV-1; HUMANS; OCCUPATIONAL EXPOSURE; PHENOTYPE; PREVALENCE; UNITED STATES;

EID: 10744232997     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502120     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR11):1-52.
2. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000;283:2417-2426.
3. Lot F, Abiteboul D. Occupational HIV infection in France. Presented at the 4th Annual International Conference on Occupational Health for Health Care Workers; September 28-October 1, 1999; Montreal, Quebec, Canada. Abstract WP-25.
4. Perdue B, Wolde Rufael D, Mellors J, Quinn T, Margolick J. HIV-1 transmission by a needlestick injury despite rapid initiation of four-drug postexposure prophylaxis. Presented at the 6th Annual Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 210.
5. Beltrami EM, Luo C-C, de la Torre N, Cardo DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002;23:345-348.
6. Tack PC, Bremer JW, Harris AA, Landay AL, Kessler HA, Kuritzkes DR. Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA 1999;281:1085-1086. Letter.
7. Mehta CR, Patel N. Exact logistic regression: theory and examples. Stat Med 1995;14:2143-2160.
8. Roland ME, Martin JN, Grant RM, et al. Who is the source of HIV exposure in the San Francisco Post-Exposure Prevention (PEP) Project? Presented at the 7th Annual Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 197.
9. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with human immunodeficiency virus type 1 seroconverters in the United States, 1992-1998. J Infect Dis 2000;182:330-333.
10. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
11. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131:502-506.
12. Leigh-Brown AJ, Precious HM, Whitcomb JM, et al. Reduced susceptibility of human immunodeficiency virus type 1 (HIV 1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000;74:10269-10273.
13. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929.
14. Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr 1998;7:42-45.
15. Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. J Infect Dis 2000;181:1475-1478.
16. Pedraza MA, del Romero J, Roldan F, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999;21:120-125.
17. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385-393.
18. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.
19. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
20. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-564.
21. Blanche S, Rouzioux C, Mandelbrot L, Delfraissy JF, Mayaux MJ. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. Presented at the 6th Annual Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL Abstract 267.
22. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-F127.
23. Verhofsted C, Van Wanzeele F, Van Der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-2546.